Regulatory T Cells and M2 Macrophages Present Diverse Prognostic Value in Gastric Cancer Patients with Different Clinicopathologic Characteristics and Chemotherapy Strategies

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2019 Jun 9

PMID 31174544

Citations 32

Authors

Xu Liu

Danhua Xu

Chen Huang

Yixian Guo

Shuchang Wang

Chunchao Zhu

Jia Xu

Zizhen Zhang

Yanying Shen

Wenyi Zhao

Gang Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Gastric cancer (GC) remains a refractory cancer worldwide. Currently, exploring the differences of the immune status in GC patients with different subgroups might provide promising immunotherapeutic approaches for the treatment of GC.

Methods: In this study, a total of 598 surgically resected FFPE primary gastric cancer samples were assessed for FOXP3, CD163, CD3, CD8, and PD-L1 markers. The correlations between the immune markers expression and clinicopathological features and prognosis were investigated retrospectively.

Results: In general, PD-L1, CD3, and CD8 could be regarded as favorable prognostic factors. Our data demonstrated that high infiltration of FOXP3 Treg indicates better prognosis in stage I-II patients, while the converse outcome was noted in stage III-IV patients. Our data also confirmed different prognostic value in different pathological classifications, chemotherapy strategies, and locations, with or without lymph node metastasis. Also, M2 macrophages indicated poor prognosis in general. However, high M2 macrophage infiltration suggests a favorable prognosis in signet ring cell carcinoma and mucinous adenocarcinoma. Moreover, the prognostic value of the two indices when they are combined is reported.

Conclusions: These results suggested that different immune statuses are exhibited in different subgroups of GC, which may direct further understanding of the immune status of GC as well as provide a further theoretical basis and potential targets for GC immunotherapy.

Citing Articles

CHST1 as a prognostic-related biomarker in gastric cancer correlating with immune infiltration.

Gui L, Yu J, Tan J, Zhong G, Wang Y, Zhong L Heliyon. 2025; 11(3):e42124.

PMID: 39944327 PMC: 11815906. DOI: 10.1016/j.heliyon.2025.e42124.

Association of PD-1 + Treg/PD-1 + CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment.

Liu X, Xu D, Zhou C, Zhong Y, Geng H, Huang C J Transl Med. 2024; 22(1):1152.

PMID: 39731106 PMC: 11673346. DOI: 10.1186/s12967-024-05867-4.

A novel M2-like tumor associated macrophages-related gene signature for predicting the prognosis and immunotherapy efficacy in gastric cancer.

Li X, Qu X, Wang N, Li S, Zhao X, Lin K Discov Oncol. 2024; 15(1):353.

PMID: 39150637 PMC: 11329457. DOI: 10.1007/s12672-024-01221-8.

Correlation between Tregs and ICOS-induced M2 macrophages polarization in colorectal cancer progression.

Xu J, Gao Y, Ding Y, Feng Y, Chen J, Zhang S Front Oncol. 2024; 14:1373820.

PMID: 39104717 PMC: 11298335. DOI: 10.3389/fonc.2024.1373820.

Complex Role of Regulatory T Cells (Tregs) in the Tumor Microenvironment: Their Molecular Mechanisms and Bidirectional Effects on Cancer Progression.

Wang Y, Li J, Nakahata S, Iha H Int J Mol Sci. 2024; 25(13).

PMID: 39000453 PMC: 11242872. DOI: 10.3390/ijms25137346.

References

Bockorny B, Pectasides E . The emerging role of immunotherapy in gastric and esophageal adenocarcinoma. Future Oncol. 2016; 12(15):1833-46. DOI: 10.2217/fon-2016-0103. View

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

Lee H, Chae S, Lee Y, Kim M, Lee H, Lee B . Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008; 99(10):1704-11. PMC: 2584941. DOI: 10.1038/sj.bjc.6604738. View

Tanaka A, Sakaguchi S . Regulatory T cells in cancer immunotherapy. Cell Res. 2016; 27(1):109-118. PMC: 5223231. DOI: 10.1038/cr.2016.151. View

Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H . Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007; 13(7):2151-7. DOI: 10.1158/1078-0432.CCR-06-2746. View

Perrone G, Ruffini P, Catalano V, Spino C, Santini D, Muretto P . Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer. 2008; 44(13):1875-82. DOI: 10.1016/j.ejca.2008.05.017. View

Gao Q, Qiu S, Fan J, Zhou J, Wang X, Xiao Y . Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007; 25(18):2586-93. DOI: 10.1200/JCO.2006.09.4565. View

Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J . PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLoS One. 2017; 12(8):e0182692. PMC: 5552131. DOI: 10.1371/journal.pone.0182692. View

Xing X, Guo J, Ding G, Li B, Dong B, Feng Q . Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology. 2018; 7(3):e1356144. PMC: 5790386. DOI: 10.1080/2162402X.2017.1356144. View

10.

Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K . Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016; 22(6):679-84. DOI: 10.1038/nm.4086. View

11.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

12.

Ngambenjawong C, Gustafson H, Pun S . Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017; 114:206-221. PMC: 5581987. DOI: 10.1016/j.addr.2017.04.010. View

13.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

14.

Nagase H, Takeoka T, Urakawa S, Morimoto-Okazawa A, Kawashima A, Iwahori K . ICOS Foxp3 TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2016; 140(3):686-695. DOI: 10.1002/ijc.30475. View

15.

Zheng X, Song X, Shao Y, Xu B, Chen L, Zhou Q . Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis. Oncotarget. 2017; 8(34):57386-57398. PMC: 5593650. DOI: 10.18632/oncotarget.18065. View

16.

Muro K, Chung H, Shankaran V, Geva R, Catenacci D, Gupta S . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17(6):717-726. DOI: 10.1016/S1470-2045(16)00175-3. View

17.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

18.

. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14(2):101-12. DOI: 10.1007/s10120-011-0041-5. View

19.

Li Z, Li D, Tsun A, Li B . FOXP3+ regulatory T cells and their functional regulation. Cell Mol Immunol. 2015; 12(5):558-65. PMC: 4579651. DOI: 10.1038/cmi.2015.10. View

20.

Kawamura H, Kondo Y, Osawa S, Nisida Y, Okada K, Isizu H . A clinicopathologic study of mucinous adenocarcinoma of the stomach. Gastric Cancer. 2001; 4(2):83-6. DOI: 10.1007/pl00011728. View